全球融合切片检查市场规模、份额、趋势和成长分析报告（2026-2034年）

融合切片检查市场规模预计将从 2025 年的 14.5 亿美元成长到 2034 年的 29.8 亿美元，2026 年至 2034 年的复合年增长率为 8.3%。

融合切片检查市场正经历显着增长，这主要得益于影像技术的进步和前列腺癌发病率的上升。融合切片检查结合了传统超音波影像和磁振造影（MRI），提高了前列腺癌诊断的准确性。这项创新技术能够对可疑病灶进行标靶取样，在提高临床显着癌症检出率的同时，最大限度地减少不必要的切片检查。随着人们对前列腺癌的认识不断提高以及筛检指南的不断完善，预计对融合切片检查的需求将持续增长，从而推动该市场强劲发展。

此外，对个人化医疗的日益重视正在影响融合切片检查的发展趋势。提供更精确的肿瘤特征讯息，使医疗专业人员能够为每位患者制定个人化的治疗方案。这种向标靶治疗的转变在肿瘤学领域尤其重要，因为了解肿瘤的特定生物学特征会显着影响治疗结果。随着医疗系统越来越多地采用精准医疗方法，融合切片检查市场有望受益于先进诊断工具的整合，从而改善患者照护并优化资源利用。

此外，微创手术的兴起也推动了融合切片检查技术的应用。患者越来越倾向于选择能够减少不适感和缩短恢復时间的治疗方案，这使得融合切片检查成为传统切片检查方法的理想替代方案。使用者友善设备的研发以及针对医疗专业人员的培训计画也进一步促进了这项技术的应用。随着融合切片检查市场的不断发展，持续的研发将在拓展其应用范围和提高诊断准确性方面发挥关键作用，最终有助于改善前列腺癌患者的治疗效果。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 绘製渗透率和成长前景图
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

第四章 全球融合切片检查市场（依技术目标划分）

• 市场分析、洞察与预测
• DNA
• RNA
• 蛋白质

5. 全球融合切片检查市场（依产品划分）

• 市场分析、洞察与预测
• 多基因检测
• 单基因检测
• 伴随诊断
• 调查工具包（仅供参考）

6. 全球融合切片检查市场（按应用领域划分）

• 市场分析、洞察与预测
• 肿瘤学
• 神经病学
• 感染疾病
• 心血管疾病

7. 全球融合切片检查市场（依技术划分）

• 市场分析、洞察与预测
• 次世代定序（NGS）
• 聚合酵素链锁反应（PCR）
• 数位PCR
• 奈米弦技术

8. 全球融合切片检查市场（按地区划分）

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商格局（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • HologicInc
  • Exact Sciences Corporation
  • Myriad GeneticsInc
  • BioRad LaboratoriesInc
  • Invivoscribe
  • Leica Biosystems
  • AffymetrixInc
  • Qiagen NV
  • BD（Becton, Dickinson And Company）
  • Agilent TechnologiesInc
  • Genomic Health
  • Sysmex Corporation
  • Beckman CoulterInc
  • Thermo Fisher Scientific Inc
  • IlluminaInc

The Fusion Biopsy Market size is expected to reach USD 2.98 Billion in 2034 from USD 1.45 Billion (2025) growing at a CAGR of 8.3% during 2026-2034.

The fusion biopsy market is experiencing significant growth, driven by advancements in imaging technologies and the increasing prevalence of prostate cancer. Fusion biopsy combines traditional ultrasound imaging with magnetic resonance imaging (MRI) to enhance the accuracy of prostate cancer diagnosis. This innovative approach allows for targeted sampling of suspicious lesions, improving the detection rate of clinically significant cancers while minimizing unnecessary biopsies. As awareness of prostate cancer rises and screening guidelines evolve, the demand for fusion biopsy procedures is expected to increase, positioning this market for robust expansion.

Moreover, the growing emphasis on personalized medicine is influencing the fusion biopsy landscape. By providing more precise information about tumor characteristics, fusion biopsy enables healthcare providers to tailor treatment plans to individual patients. This shift towards targeted therapies is particularly relevant in oncology, where understanding the specific biology of a tumor can significantly impact treatment outcomes. As healthcare systems increasingly adopt precision medicine approaches, the fusion biopsy market is likely to benefit from the integration of advanced diagnostic tools that enhance patient care and optimize resource utilization.

Additionally, the rise of minimally invasive procedures is driving the adoption of fusion biopsy techniques. Patients are increasingly seeking options that reduce discomfort and recovery time, making fusion biopsy an attractive alternative to traditional biopsy methods. The development of user-friendly devices and training programs for healthcare professionals is further facilitating the adoption of this technology. As the fusion biopsy market continues to evolve, ongoing research and innovation will play a crucial role in expanding its applications and improving diagnostic accuracy, ultimately contributing to better patient outcomes in the fight against prostate cancer.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Tech Target

• DNA
• RNA
• Protein

By Product

• Multi-gene Panels
• Single-gene Tests
• Companion Diagnostics
• Research Use Only (RUO) Kits

By Application

• Oncology
• Neurology
• Infectious Diseases
• Cardiovascular Diseases

By Technology

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Digital PCR
• NanoString Technologies

COMPANIES PROFILED

• Hologic, Inc, Exact Sciences Corporation, Myriad Genetics, Inc, BioRad Laboratories, Inc, Invivoscribe, Leica Biosystems, Affymetrix, Inc, Qiagen NV, BD Becton, Dickinson and Company, Agilent Technologies, Inc, Genomic Health, Sysmex Corporation, Beckman Coulter, Inc, Thermo Fisher Scientific Inc, Illumina, Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL FUSION BIOPSY MARKET: BY TECH TARGET 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Tech Target
• 4.2. DNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. RNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Protein Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL FUSION BIOPSY MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Multi-gene Panels Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Single-gene Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Companion Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Research Use Only (RUO) Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL FUSION BIOPSY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL FUSION BIOPSY MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Technology
• 7.2. Next-Generation Sequencing (NGS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Polymerase Chain Reaction (PCR) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Digital PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. NanoString Technologies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL FUSION BIOPSY MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Tech Target
  • 8.2.2 By Product
  • 8.2.3 By Application
  • 8.2.4 By Technology
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Tech Target
  • 8.3.2 By Product
  • 8.3.3 By Application
  • 8.3.4 By Technology
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Tech Target
  • 8.4.2 By Product
  • 8.4.3 By Application
  • 8.4.4 By Technology
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Tech Target
  • 8.5.2 By Product
  • 8.5.3 By Application
  • 8.5.4 By Technology
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Tech Target
  • 8.6.2 By Product
  • 8.6.3 By Application
  • 8.6.4 By Technology
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL FUSION BIOPSY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 HologicInc
  • 10.2.2 Exact Sciences Corporation
  • 10.2.3 Myriad GeneticsInc
  • 10.2.4 BioRad LaboratoriesInc
  • 10.2.5 Invivoscribe
  • 10.2.6 Leica Biosystems
  • 10.2.7 AffymetrixInc
  • 10.2.8 Qiagen N.V
  • 10.2.9 BD (Becton, Dickinson And Company)
  • 10.2.10 Agilent TechnologiesInc
  • 10.2.11 Genomic Health
  • 10.2.12 Sysmex Corporation
  • 10.2.13 Beckman CoulterInc
  • 10.2.14 Thermo Fisher Scientific Inc
  • 10.2.15 IlluminaInc